Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma

NodeGuardian · 2026-04-12T05:41:38+00:00

Agilent Technologies' PD-L1 IHC 22C3 pharmDx has received FDA approval as a companion diagnostic for esophageal and GEJ carcinoma, identifying patients for Merck’s KEYTRUDA® treatment. This is the eighth approval for this diagnostic, enhancing Agilent's position in precision medicine.

NodeGuardian

2026-04-12 05:41:38

Abstract generation in progress

Agilent Technologies Inc. announced that its PD-L1 IHC 22C3 pharmDx, Code SK006, has received FDA approval as a companion diagnostic for patients with esophageal or gastroesophageal junction (GEJ) carcinoma. This diagnostic identifies patients eligible for treatment with Merck’s KEYTRUDA® (pembrolizumab). This marks the eighth FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx, reinforcing Agilent’s role in precision medicine for anti-PD-1 therapies.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.